Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted a registrational study protocol to the U.S. Food and Drug Administration for its SkinJect therapy in Gorlin syndrome, a rare …
ICYMI: Medicus Advances SkinJect Into Registrational Study for Rare Disorder Read More
PHILADELPHIA, PA — Medicus Pharma (Nasdaq: MDCX) has advanced its SkinJect® treatment into registrational development for Gorlin Syndrome, a rare genetic disorder that causes recurring skin cancers and often requires …
Medicus Pharma Seeks FDA Path for Rare Skin Cancer Disorder Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has secured access to up to $22 million in new financing, providing the biotechnology company with additional capital to fund clinical development …
Medicus Secures $22 Million Financing to Extend Cash Runway Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported expanded Phase 2 data for its SkinJect skin cancer therapy and advanced development of its Teverelix prostate cancer program during the …
Medicus Advances Cancer Pipeline as Losses Widen Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported additional Phase 2 trial data showing higher-dose treatment with its experimental SkinJect therapy produced stronger response rates in patients with nodular …
Medicus Pharma (Nasdaq: MDCX) Advances Lead Skin Cancer Regimen Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported additional Phase 2 trial data showing a dose-response relationship for its SkinJect treatment candidate for nodular basal cell carcinoma, with the …
Medicus Pharma Reports Expanded Phase 2 Skin Cancer Trial Data Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said its chief executive and leadership team met with U.S. lawmakers on Capitol Hill last month to seek support for regulatory and …
Medicus Pharma Meets Lawmakers to Advance SkinJect Program Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it submitted an Orphan Drug Designation application to the U.S. Food and Drug Administration for SkinJect (D-MNA) to treat basal cell …
Medicus Pharma Submits Orphan Drug Application for SkinJect Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present Phase 1 clinical data for its investigational drug Teverelix at the American Association of Clinical Endocrinology Annual Meeting, …
Medicus Pharma to Present Phase 1 Data on Teverelix at AACE 2026 Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present new Phase 1 clinical data on Teverelix, its investigational long-acting gonadotropin-releasing hormone antagonist, at the American Association of …
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting Read More